BCRX — BioCryst Pharmaceuticals Inc

Founder-Led

Stock analysis, trade plans, and proprietary indicators by Trend Edge.

About BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated and seasonal influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat HAE. Read full Trend Edge analysis →

Trend Edge Proprietary Indicators

Key Metrics

Current Price$9.02
Market Cap$2.32B
Float221.5M
Shares Outstanding254.2M
P/E (Forward)75.19
Price/Sales (TTM)2.62
vs. Analyst Target+138.4% to analyst PT
Profit Margin-51.71%
Operating Margin (TTM)-2.45%
Revenue (TTM)$886M
Dividend RateNone
Analyst Target Price$21.50 (12 analysts)

Financial History

Annual Revenue & Earnings History

YearRevenueNet IncomeGross ProfitEBITDA
2020 $17.8M -$183M $16.1M -$168M
2021 $157M -$184M $150M -$122M
2022 $271M -$247M $264M -$144M
2023 $331M -$227M $327M -$116M
2024 $451M -$88.9M $438M $12.8M
2025 $875M $264M $856M $348M

Recent Quarterly Revenue & Net Income

QuarterRevenueNet Income
Jun 2025 $163M $5.1M
Sep 2025 $159M $12.9M
Dec 2025 $407M $246M
Mar 2026 $156M -$722M

Ownership & Float

Insider Ownership1.1%
Institutional Ownership94.1%
Short Float16.9%
% of All Funds Holding3.39%
Number of Funds Holding279

Current Moving Averages

Trend Edge tracks near-term, medium-term, cyclical, and secular moving averages across weekly and monthly timeframes to identify trend structure at every horizon.

TimeframeSMAValueTrend Context
Weekly10-Week SMA$9.11Near-term / short-term trend
Weekly40-Week SMA$7.87Medium-term trend
Weekly80-Week SMA$8.15Cyclical trend (business cycle)
Weekly200-Week SMA$8.20Secular trend (multi-year)
Monthly10-Month SMA$8.12Near-term monthly trend
Monthly20-Month SMA$8.25Medium-term monthly trend
Monthly40-Month SMA$7.51Secular monthly trend

Volume Shelves — Support & Resistance

Trend Edge identifies volume shelves: price zones where historically elevated trading volume creates structural support or resistance. A volume shelf forms when a disproportionate share of cumulative volume was transacted at a specific price level, making it a high-conviction anchor for future price reactions.

Price LevelTypeVolume RatioAge
$10.70 resistance 1.15x 10 months ago
$4.20 support 1.30x 23 months ago

Historical Earnings Reactions (126 events)

TimeframeAvg ReturnMedianWin RateBestWorst
Gap 0.57% 0.06% 50.00% 42.53% -23.50%
1 Day 0.22% -0.74% 42.86% 27.85% -23.62%
1 Week 1.45% -0.98% 46.83% 45.27% -42.45%
2 Weeks 2.74% 0.12% 50.00% 56.65% -55.27%
1 Month 6.06% 1.13% 52.38% 134.50% -50.72%

Next earnings: May 6, 2026

Seasonality & Day-of-Week Patterns

Monthly Seasonality

MonthAvg ReturnWin RateSamples
Jan2.5%56.3%32
Feb0.1%53.1%32
Mar1.7%37.5%32
Apr4.6%54.5%33
May6.3%56.3%32
Jun2.7%59.4%32
Jul11.2%56.3%32
Aug10.0%59.4%32
Sep-4.9%34.4%32
Oct-4.7%50.0%32
Nov3.7%46.9%32
Dec0.5%50.0%32

Day-of-Week Tendencies

DayAvg ReturnWin RateSamples
Monday 0.26% 47.2% 1523
Tuesday -0.05% 43.8% 1663
Wednesday 0.23% 47.1% 1661
Thursday -0.00% 44.2% 1629
Friday 0.28% 45.2% 1623

Top Institutional Holders

Institutional holder breakdown coming soon.

Total institutional ownership: 94.1%

Insider Transactions — Smart Summary

Total insider ownership: 1.1%

Founder-led management: Yarlagadda S. Babu (Chief Discovery Officer)

12-Month Insider Activity Summary

Total Filings9
Net Value-$2.2M
Net Shares Change-148,280
% of Float-0.1%
C-Suite Filings5
Clusters Detected0

Key Insiders

NameTitleNet ValueFilingsActivity
Barnes Alane P Chief Legal Officer -$2.2M 5 N/A
Stonehouse Jon P -$1.7M 1 N/A
HEGGIE THERESA -$482,410.73 2 2 sell
SANDERS MACHELLE -$68,544 1 N/A

Significant Filings

DateInsiderTitleNet ValuePrice After
2026-03-24 HEGGIE THERESA -$190,244.73 Transaction at $8.21, now +9.9%
2025-08-15 HEGGIE THERESA -$292,166 Transaction at $6.43, now +40.4%
2025-12-03 Barnes Alane P Chief Legal Officer -$871,936.192 Transaction at $5.21, now +73.0%
2025-12-23 Barnes Alane P Chief Legal Officer -$291,807.27 Transaction at $7.53, now +19.8%
2025-12-16 Barnes Alane P Chief Legal Officer -$226,904.3 Transaction at $7.61, now +18.5%
2025-11-17 SANDERS MACHELLE -$68,544 Transaction at $7.14, now +26.3%

View full insider transaction history on Trend Edge →

AI Consult Analysis

Trend Edge's AI Consult feature delivers a comprehensive, multi-layer trade plan for BioCryst Pharmaceuticals Inc (BCRX) powered by Claude Opus — Anthropic's most capable AI model. The analysis covers five layers: technical analysis (near-term, medium-term, cyclical, and secular trend, momentum, volume shelf support and resistance, breakout and breakdown signals), qualitative analysis (business model, competitive moat, sector dynamics), insider sentiment (buy and sell signals from executive and director transactions), share stats analysis (institutional accumulation, fund positioning, short float squeeze potential), and fundamental analysis (valuation, revenue growth, profit margin, earnings quality).

AI Consult synthesizes all five layers into a single bullish or bearish thesis with explicit entry, exit, stop loss, and take profit levels — giving you a complete, AI-powered trade plan with defined risk/reward. Whether you are building a long position, initiating a short, or looking for a reversal setup, AI Consult identifies the highest-probability signal from the current trend.

Get the full AI Consult analysis for BCRX on Trend Edge →